Granzyme B and Its Role in Thyroid Cancer: A Survey

Abstract

Granzyme B (GrB), a serine protease released by cytotoxic lymphocytes, is crucial in mediating apoptosis in thyroid cancer cells, serving as a potential therapeutic target. This survey explores GrB's role within the immune response, emphasizing its interaction with the tumor microenvironment (TME) and its impact on cancer progression and treatment outcomes. The TME influences immune cell infiltration and function, presenting challenges and opportunities for enhancing immunotherapy efficacy. Understanding the heterogeneity and dynamics of tumor-infiltrating immune cells is vital for developing personalized therapeutic strategies that optimize treatment efficacy. This paper highlights innovative approaches, including GrB-targeted therapies and combination treatments, to overcome TME-induced immunosuppression and improve therapeutic precision. Future research should focus on elucidating GrB's mechanisms in immune modulation and its potential in combination therapies, aiming to enhance the immune-mediated eradication of cancer cells. By advancing our understanding of GrB, cytotoxic lymphocytes, and TME interactions, we can develop targeted interventions that leverage the immune system's power, offering promising avenues for improving thyroid cancer treatment strategies and patient outcomes.

1 Introduction

1.1 Granzyme B and Its Significance

Granzyme B (GrB), a serine protease produced by activated cytotoxic T lymphocytes and natural killer (NK) cells, plays a vital role in the immune system, particularly in targeting cancerous lesions such as thyroid cancer. GrB induces apoptosis in target cells by cleaving intracellular substrates, which is essential for the immune system's selective eradication of tumor cells [1, 2]. In thyroid cancer, GrB's interaction with membrane-bound 70 kDa heat shock protein (mHsp70) on tumor cells facilitates its internalization and subsequent apoptosis induction, positioning it as a potential therapeutic agent that spares normal tissues [3]. Its role in papillary thyroid carcinoma (PTC) is particularly significant, as GrB presence correlates with the cytotoxic capacity of tumor-infiltrating lymphocytes and lymph node metastasis [4].

GrB also modulates the tumor microenvironment and influences cancer progression via inflammatory pathways [1]. Its regulatory function in immune responses is crucial for aging populations, maintaining immune surveillance despite age-related declines in function [5]. This aspect is essential for developing effective cancer therapies across different age groups. GrB's historical contributions to understanding T cell-mediated cytotoxicity have been pivotal in advancing cancer immunotherapy. Its ability to mediate apoptosis through both intrinsic and extrinsic pathways underscores its therapeutic potential [6]. Furthermore, the involvement of T follicular regulatory (TFR) cells in regulating the germinal center response highlights the complexity of immune regulation in which GrB is integrated [7]. As research continues to elucidate GrB's multifaceted role, its application in immunotherapy remains a promising avenue for enhancing cancer treatment outcomes.



Figure 1: chapter structure

1.2 Cytotoxic Lymphocytes in Cancer Treatment

Cytotoxic lymphocytes, particularly cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, are essential in the immune system's defense against cancer, acting as primary executors of cell-mediated cytotoxicity. Equipped with cytotoxic molecules like perforin and granzymes, these cells induce apoptosis in target cancer cells, thereby preventing cancer progression and metastasis [8]. The effectiveness of cytotoxic lymphocytes in cancer treatment is closely tied to their infiltration of the tumor microenvironment (TME), a heterogeneous milieu affecting therapeutic outcomes [6]. The presence of these lymphocytes within the TME correlates with improved patient prognosis, as they directly target tumor cells and modulate local immune responses.

Recent advances in immunotherapy aim to enhance the function and persistence of cytotoxic lymphocytes in the TME. For instance, strategies utilizing knockout induced pluripotent stem cells (iPSCs) have been proposed to augment the expansion and controlled cytotoxicity of these cells, potentially improving their efficacy against cancer cells in vivo [9]. This approach emphasizes the potential of engineered cytotoxic lymphocytes to overcome the TME's immunosuppressive barriers. Moreover, interactions between B and T cells, as explored through probabilistic regulatory network models, shed light on the complex regulatory mechanisms governing immune responses in cancer [10]. Understanding these interactions is crucial for optimizing lymphocyte therapeutic potential in cancer treatment, reaffirming their central role in developing effective and targeted therapies.

1.3 Overview of Paper Structure

This paper comprehensively explores Granzyme B and its pivotal role in the immune response against thyroid cancer. It begins with an introduction to GrB's significance as a serine protease critical for

AI-generated, for reference only.

inducing apoptosis in cancer cells and the importance of cytotoxic lymphocytes in cancer treatment. The subsequent sections detail GrB's structural and functional roles, the biology of thyroid cancer, and the influence of the tumor microenvironment on cancer progression and therapeutic outcomes. The interactions between tumor cells and immune cells that shape the cancer landscape are also examined, emphasizing their importance in developing effective therapeutic strategies [6, 11, 3, 2, 1].

The third section investigates the relationship between GrB and cytotoxic lymphocytes, such as CD8+ T cells and NK cells, discussing factors influencing GrB expression and activity, including age-related variations and hypoxia effects. The following section focuses on GrB's mechanisms of apoptosis induction, exploring the biochemical pathways and the roles of caspases and other apoptotic factors.

The paper further analyzes the TME's influence on immune infiltration and function, examining how GrB and cytotoxic lymphocytes interact within this context to affect cancer treatment outcomes. The penultimate section discusses therapeutic implications, including strategies for targeting GrB in thyroid cancer and enhancing cytotoxic lymphocyte activity through combination therapies. Future research directions aimed at improving understanding and treatment of thyroid cancer are also suggested. The paper concludes by summarizing key findings and emphasizing GrB's potential as a therapeutic target in cancer treatment.The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Granzyme B: Structure and Function

Granzyme B (GrB) is a serine protease pivotal to the immune system, facilitating apoptosis in cancer cells by cleaving after aspartic acid residues in substrate proteins [2]. This action initiates proteolytic cascades leading to cell death, thereby aiding the immune system in clearing cancerous cells [3]. GrB is produced by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, stored in cytotoxic granules, and released with perforin to penetrate target cells. Once inside, GrB cleaves intracellular substrates, including caspases, activating both intrinsic and extrinsic apoptotic pathways [1, 12].

Beyond apoptosis, GrB exhibits pro-inflammatory properties by activating substrates involved in inflammation, crucial in the tumor microenvironment where it not only kills tumor cells but also modulates inflammation, impacting tumor progression and immune surveillance. Age-related changes in GrB expression may contribute to immune dysfunction in older populations, necessitating age-specific therapeutic strategies [5].

Research increasingly focuses on GrB's role in signaling networks. Computational models integrating deterministic and stochastic processes simulate GrB's regulatory mechanisms in response to environmental stimuli [13]. These models, along with macrophage-specific interactomes, provide frameworks for exploring GrB's multifaceted roles in immune responses and cancer biology [14].

2.2 Thyroid Cancer Biology

Thyroid cancer includes malignancies from follicular or parafollicular thyroid cells, with subtypes such as papillary, follicular, medullary, and anaplastic thyroid cancers. Papillary thyroid carcinoma (PTC) is most common, generally indolent but potentially aggressive [3]. Genetic alterations, including BRAF, RAS, and RET/PTC mutations, drive tumorigenesis via MAPK and PI3K/AKT pathway dysregulation.

The tumor microenvironment (TME) is vital in thyroid cancer progression and metastasis, composed of stromal cells, immune cells, extracellular matrix, and signaling molecules that interact with cancer cells. The expression of membrane-bound 70 kDa heat shock protein (mHsp70) on tumor cells facilitates selective targeting by immune effectors like GrB, presenting a therapeutic target [3].

Aggressive subtypes like anaplastic thyroid carcinoma exhibit rapid growth and therapy resistance, with the TME's influence on invasion and metastasis. Factors such as hypoxia and extracellular matrix changes promote progression, emphasizing the need to target TME components to enhance treatment efficacy [6, 11, 15, 16, 17]. Research into TME interactions reveals novel therapeutic targets, with markers like mHsp70 and signaling pathways offering insights for precision medicine in thyroid cancer.

2.3 Immune Response in Thyroid Cancer

The immune response to thyroid cancer involves CTLs and NK cells targeting cancer cells, with GrB mediating apoptosis to curb tumor growth and metastasis [4]. In PTC, GrB-mediated activity by tumor-infiltrating lymphocytes correlates with cervical lymph node metastasis, highlighting effective immune surveillance's importance [4]. T follicular regulatory (TFR) cells maintain immune homeostasis by preventing cytotoxic-like T follicular helper (TFH) cell development, crucial for germinal center (GC) responses [7].

GrB expression and activity are influenced by age and the TME, with hypoxia affecting CTLs' proteomic profiles, enhancing cytolytic molecule expression but upregulating inhibitory checkpoints, impacting GrB-mediated apoptosis. Age-related immune changes, like increased GrB expression, may hinder responses against thyroid cancer [4, 5].

The immune response is further complicated by cancer cell population heterogeneity, affecting treatment responses. Advanced modeling techniques, such as probabilistic regulatory networks, are essential for understanding immune interactions and cellular signaling variability, enhancing targeted therapy development [14, 10, 16, 13].

2.4 Tumor Microenvironment (TME)

The tumor microenvironment (TME) significantly influences cancer progression, metastasis, and treatment resistance. It consists of cancer cells, immune cells, stromal cells, extracellular matrix, and signaling molecules, impacting tumor behavior and therapeutic responses. The TME's role includes metabolic reprogramming, immune evasion, and modulating tumor-stromal interactions, highlighting it as a critical target for cancer therapies [6, 18, 17, 11].

Immune cell infiltration in the TME affects immunotherapy efficacy, with T cell interactions crucial for antitumor responses [19]. However, the TME can impede immune infiltration through inhibitory molecules and immunosuppressive cells, facilitating immune evasion [20].

The stochastic nature of cancer cell populations adds complexity to tumor dynamics and treatment outcomes. Stochastic models predict cancer behavior and relapse potential, emphasizing the need for specialized immune responses [21]. These models highlight TME heterogeneity challenges and the need for personalized therapeutic strategies [6].

Therapeutic strategies targeting the TME aim to disrupt its supportive role in cancer progression and enhance conventional treatments. Approaches include modulating the immune landscape, altering metabolic pathways, and targeting cellular interactions within the TME [17]. Understanding TME components and interactions is crucial for developing therapies to overcome treatment resistance and improve cancer patient outcomes.

3 Granzyme B and Cytotoxic Lymphocytes

The interaction between granzyme B and cytotoxic lymphocytes is crucial for understanding the role of these cells in cancer immunotherapy. Effective immune responses by natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are essential for successful cancer treatment. This section examines factors leading to cytotoxic lymphocyte dysfunction, affecting therapeutic efficacy and patient prognosis, and discusses age-related aspects of this dysfunction, particularly granzyme B expression in older populations.

To illustrate these concepts, Figure 2 presents a hierarchical classification of key factors affecting granzyme B expression and cytotoxic lymphocyte functionality in cancer immunotherapy. This figure highlights the impact of cytotoxic lymphocyte dysfunction, age-related granzyme B expression variability, the influence of hypoxia on CD8+ T cells, and recovery patterns in cytotoxic lymphocytes. By providing a structured overview of the complex interactions and implications for treatment strategies, the figure enhances our understanding of the multifaceted nature of immune responses in the context of cancer therapy.



Figure 2: This figure illustrates the hierarchical classification of key factors affecting granzyme B expression and cytotoxic lymphocyte functionality in cancer immunotherapy. It highlights the impact of cytotoxic lymphocyte dysfunction, age-related granzyme B expression variability, the influence of hypoxia on CD8+ T cells, and recovery patterns in cytotoxic lymphocytes, providing a structured overview of the complex interactions and implications for treatment strategies.

3.1 Impact of Cytotoxic Lymphocyte Dysfunction

Cytotoxic lymphocytes, including NK cells and CTLs, are vital for cancer immunotherapy, but their dysfunction can severely impair cancer cell targeting and elimination, affecting treatment outcomes. Genetic, epigenetic, and stochastic factors contribute to variability in cancer cell responses, complicating treatment efficacy predictions [16]. The tumor microenvironment (TME) exacerbates this complexity by altering immune cell function through metabolic reprogramming and immune suppression, promoting tumor growth and metastasis [18].

Understanding T cell recruitment and retention dynamics is crucial for anti-tumor activity, as the TME can impede cytotoxic lymphocyte infiltration and retention, reducing therapeutic success [19]. The expression of cytotoxic molecules, including perforin and granzyme B, by tumor-infiltrating lymphocytes is critical for their killing capacity, providing insights into their functional status and potential impact on cancer treatment [4].

Age-related immune changes further complicate cancer therapy. In elderly patients, such as those with acute myeloid leukemia (AML), NK cells exhibit impaired functionality and altered phenotypes, affecting recovery post-chemotherapy and limiting cytotoxic potential [22]. Recognizing these variations is vital for developing tailored therapeutic strategies that enhance cytotoxic lymphocyte efficacy across diverse patient demographics.

Interactions among syntaxin-binding proteins, such as STXBP1 and STXBP2, complement the cytotoxic activity of NK and T cells, revealing the complexity of intracellular signaling pathways regulating lymphocyte function [8]. Addressing cytotoxic lymphocyte dysfunction through targeted interventions is critical for improving cancer treatment outcomes and harnessing the immune system's full potential against malignancies.

3.2 Age-Related Expression of Granzyme B

Granzyme B (GrB) expression varies with age, significantly influencing immune function and overall immune response effectiveness. Older adults exhibit higher GrB levels compared to younger individuals, with increased Granzyme K expression, indicating a compensatory mechanism that may affect immune responses to infections and malignancies [5].

These age-related changes in GrB expression are particularly relevant for cancer and vaccination responses. While elevated GrB levels may enhance cytotoxic capacity, they may also indicate age-associated immune dysregulation, affecting the balance between pro-inflammatory and anti-inflammatory responses. This dysregulation, particularly the increased expression of GrB and K in older adults, could compromise vaccine efficacy, necessitating tailored vaccination strategies to optimize responses in this demographic [23, 14, 6, 19, 5].

Post-treatment immune cell recovery kinetics reveal that age-related differences in GrB expression impact the functional recovery of cytotoxic lymphocytes. NK cells, key GrB producers, exhibit slower functionality recovery than CD8 T cells and T cells in older adults [22]. This delayed recovery may reduce the ability to control tumor growth and infection in elderly patients, emphasizing the need for age-specific therapeutic interventions that consider the altered immune landscape.

Understanding age-related GrB expression and its effects on immune function is essential for enhancing immune responses in older adults. Optimizing cancer immunotherapies and vaccine formulations must address the unique challenges posed by the aging immune system, which can influence treatment efficacy. Recent advances in single-cell technologies enable detailed profiling of tumor-infiltrating immune cells, providing insights into their functional diversity and interactions within the TME, crucial for developing effective therapeutic strategies for older patients [17, 6].

3.3 Hypoxia and Proteome Influence on CD8+ T Cells

Hypoxic conditions in the tumor microenvironment (TME) profoundly affect cytotoxic lymphocytes, particularly CD8+ T cells. Low oxygen levels induce proteomic alterations, modulating immune efficacy. This reprogramming can enhance certain cytotoxic functions while inhibiting others, affecting the immune response against cancer cells [23].

As illustrated in Figure 3, the impact of hypoxia on CD8+ T cells and their proteome is significant, highlighting the intricate interplay with immune cells and the functionality of NK cells within the TME. Hypoxia impacts CD8+ T cells by influencing the expression and activity of cytotoxic molecules like Granzyme B. Hypoxia-induced changes may upregulate GrB expression, enhancing cytotoxic capacity. However, hypoxic conditions can also upregulate inhibitory checkpoints and downregulate pro-inflammatory cytokine production, such as IL-2, limiting CTL cytotoxic potential and fostering local immunosuppression, aiding tumor immune evasion and progression. These metabolic alterations underscore the complex interplay between tumor and immune cells, where nutrient competition and waste accumulation exacerbate challenges to effective anti-tumor immunity [23, 18, 19].

NK cells, also crucial GrB producers, are influenced by hypoxic conditions within the TME. Despite hypoxia, NK cells maintain significant numbers and functionality post-chemotherapy in AML patients, highlighting their potential in immunotherapeutic strategies despite adverse TME conditions [22].

Understanding the interplay between hypoxia, proteomic changes, and cytotoxic lymphocyte functionality is essential for developing effective cancer immunotherapies. Elucidating mechanisms through which hypoxic conditions reconfigure immune cell proteomes and metabolic pathways can inform targeted strategies to enhance cytotoxic potential. This understanding is crucial for overcoming TME limitations that impair immune cell function during cancer treatment. Recent advances in single-cell technologies and comprehensive profiling of tumor-infiltrating immune cells aim to improve therapeutic outcomes in cancer immunotherapy, leading to more effective treatment strategies for patients [17, 23, 6, 19].

3.4 Recovery Patterns in Cytotoxic Lymphocytes

The recovery and resilience of cytotoxic lymphocytes, including NK cells and CTLs, following cancer treatment are vital for sustained efficacy of immunotherapeutic strategies. Post-treatment recovery is influenced by various factors, including the TME and inherent variability in cellular signaling pathways. Insights into distinct recovery patterns of immune cells within the TME are crucial for tailoring treatment regimens, directly impacting therapeutic efficacy and patient outcomes in cancer care. Understanding these dynamics can enhance targeted therapies, improve immune responses, and lead to more effective management of various cancer types [23, 24, 22, 6, 11].



Figure 3: This figure illustrates the impact of hypoxia on CD8+ T cells and their proteome, highlighting the interplay with immune cells and NK cell functionality in the tumor microenvironment.

Stochastic modeling approaches simulate lymphocyte recovery dynamics and cancer cell interactions, offering insights into treatment effects on lymphocyte viability and functionality. These models consider birth and death rates of cancer cells and lymphocytes, incorporating therapeutic interventions and natural immune interactions [21]. By capturing the probabilistic nature of these interactions, stochastic models elucidate cytotoxic lymphocyte resilience patterns, highlighting their capacity for effective immune responses post-treatment.

Variability in signaling responses among individual lymphocytes is crucial for understanding recovery patterns. This cell-to-cell variability is particularly relevant for deciphering complex signaling pathways governing apoptosis and other immune functions. Minimal models of signaling networks account for this variability, providing insights into how cytotoxic lymphocytes adapt to post-treatment environments and maintain their cytotoxic potential [13]. These models emphasize personalized approaches in cancer therapy, informing strategies to enhance immune cell resilience and recovery across diverse patient populations.

Recovery patterns of cytotoxic lymphocytes are shaped by stochastic processes and signaling variability, both critical for determining cancer immunotherapy success. Utilizing insights from comprehensive profiling of tumor-infiltrating immune cells within the TME can inform more effective treatment protocols that enhance long-term functionality of these immune cells. This approach addresses cancer-immune evasion mechanisms and holds potential to significantly improve clinical outcomes and prognoses for cancer patients, particularly with advancements in single-cell technologies enabling a deeper understanding of dynamic interactions between cancer cells and their environment [6, 24, 11].

4 Mechanisms of Apoptosis Induction

4.1 Biochemical Pathways of Granzyme B-Induced Apoptosis

Granzyme B (GrB) is pivotal in apoptosis, acting through both intrinsic and extrinsic pathways. The intrinsic, or mitochondrial, pathway involves mitochondrial ultrastructure crucial for bioenergetics and apoptosis, where GrB cleaves pro-apoptotic factors, leading to cytochrome c release and caspase activation [15, 2]. The extrinsic pathway, initiated by death receptors like FAS, activates caspase-8, which GrB can bypass by directly entering cells via perforin, cleaving substrates to trigger apoptosis [25, 3]. GrB's dual pathway engagement underscores its versatility as an apoptotic effector.

Mathematical models reveal the probabilistic nature of apoptotic responses, highlighting the complex interplay of signaling pathways [12]. Beyond apoptosis, GrB influences inflammation and tissue remodeling by cleaving cytokines and extracellular matrix components, impacting the tumor microenvironment and cancer progression [1]. GrB's binding to mHsp70 on tumor cells enhances its therapeutic potential [3].

High-resolution mass spectrometry links protein abundance changes to functional outcomes in CTLs under varying oxygen levels, emphasizing the significance of the proteomic landscape in GrB activity and apoptosis [23].

4.2 Intrinsic and Extrinsic Apoptotic Pathways

Apoptosis involves intrinsic and extrinsic pathways, both linked to GrB, a key serine protease in immune-mediated cell death. The intrinsic pathway, governed by mitochondrial ultrastructure, is activated by stress signals leading to cytochrome c release and caspase-9 activation, with GrB promoting mitochondrial membrane permeabilization [15, 2]. The extrinsic pathway initiates through death receptor engagement, forming the DISC and activating caspase-8 [25]. GrB enters cells via perforin, activating executioner caspases and cleaving Bid, bridging both pathways for robust apoptosis [3].

Computational models illustrate GrB's integration into apoptotic networks, capturing the stochastic nature of cell death decisions [12]. Understanding GrB's dual role enhances its therapeutic potential in targeting cancer cells, especially in immune-mediated therapies.

4.3 Role of Caspases and Apoptotic Factors

Caspases, central to apoptosis, act as initiators and executioners, activated through proteolytic cleavage in response to apoptotic signals, leading to cell death [26]. In the intrinsic pathway, cytochrome c release activates caspase-9 and executioner caspases, orchestrating cellular dismantling, regulated by the Bcl-2 family [15]. The extrinsic pathway involves death receptor-triggered DISC assembly, activating caspase-8, crucial for apoptotic signaling [12, 26].

IAPs modulate apoptosis by inhibiting active caspases, adding regulatory complexity [26]. Understanding caspases and apoptotic factors is crucial for developing therapies targeting apoptosis in resistant cancer cells, enhancing chemotherapy efficacy by targeting pathways contributing to cancer survival [15, 26].

4.4 Variability and Stochasticity in Apoptosis Induction

Apoptosis induction in cancer cells is characterized by variability and stochasticity, influencing cell death timing and execution. This stochastic nature stems from signaling network intricacies, where fluctuations lead to diverse outcomes [16]. Variability arises from differences in protein expression, post-translational modifications, and pathway interactions.

Minimal signaling models capture stochastic variability, predicting probabilistic cell fate outcomes [13]. Understanding stochasticity in apoptosis is vital for therapeutic strategies targeting cancer cells, minimizing off-target effects. Insights from modeling apoptotic networks can identify regulatory nodes to enhance cancer cell responsiveness, improving treatment by addressing variability in apoptosis responses from genetic, epigenetic, and stochastic factors [12, 16, 13].

5 Tumor Microenvironment and Immune Infiltration

5.1 Implications of Tumor Microenvironment on Apoptosis

The tumor microenvironment (TME) profoundly affects apoptosis pathways and immune cell function, influencing cancer progression and resistance to therapy. This environment, composed of cancer cells, immune cells, stromal cells, and the extracellular matrix (ECM), modulates apoptotic and immune responses, impacting tumor behavior and treatment outcomes. Factors like hypoxia, oxidative stress, and ECM modifications drive interactions within the TME, altering tumor dynamics [23, 6, 20, 16, 17].

A hallmark of the TME is its capacity to reprogram cancer cell metabolism, skewing the balance toward survival pathways that enable evasion of apoptosis and resistance to therapy [18]. Hypoxic conditions exacerbate this by stabilizing hypoxia-inducible factors (HIFs), which upregulate anti-apoptotic proteins and suppress pro-apoptotic factors, promoting cancer cell survival [11].

The TME also impairs immune cell function, particularly CD8+ T cells and natural killer (NK) cells, by creating physical and biochemical barriers. Inhibitory molecules and immunosuppressive cells suppress immune responses, aiding tumor immune evasion [20]. The dynamic interplay between immune cells and TME components is crucial for immune-mediated apoptosis efficacy in cancer cells.

Stochastic models capture TME interaction complexities, offering insights into their effects on apoptosis signaling and immune cell function. These models highlight the need for personalized therapies that adapt to the evolving TME, suggesting innovative strategies to overcome treatment resistance and improve outcomes [21].

Understanding the TME is vital for developing targeted therapies that disrupt tumor-promoting signals, enhancing treatment efficacy and reducing resistance [24, 6, 11, 16, 17].

5.2 Immune Cell Infiltration and TME Interaction

Immune cell infiltration into the tumor microenvironment (TME) is a dynamic process crucial for cancer immunotherapy success. The TME comprises diverse components, including cancer and immune cells, with interactions among proteins in immune cells like macrophages and cytotoxic T lymphocytes being key to modulating immune responses. For instance, protein-protein interaction networks in macrophages reveal pathways critical for immune activation and apoptosis, while hypoxia-induced proteomic changes in cytotoxic T lymphocytes (CTLs) affect their functions [23, 14].

T cell movement and interaction kinetics within the TME are essential for understanding infiltration dynamics. T cells navigate a challenging environment of dense ECM and immunosuppressive cytokines, which can hinder their infiltration and retention, limiting cytotoxic potential [19].

Theoretical perspectives on T cell kinetics emphasize recruitment and retention mechanisms for sustained anti-tumor activity. Recruitment involves T cell entry into tumors, while retention maintains their presence and activity. The balance between metabolic processes and immune cell function is crucial, as TME fluctuations, such as hypoxia, impact CTL and NK cell proliferation and capabilities [23, 18, 6, 16, 17].

Interactions between immune cells and TME components are dynamic. Tumor-infiltrating lymphocytes (TILs) modulate the TME by secreting cytokines and chemokines, recruiting more immune cells, and influencing tumor progression. Advances in single-cell technologies, such as single-cell RNA sequencing, have revealed TIL diversity and mechanisms underlying cancer-immune evasion, informing immunotherapeutic strategies [23, 6, 19]. Conversely, the TME can alter immune cell function through metabolic reprogramming and immunosuppressive factors, dampening immune responses.

Understanding immune cell infiltration and TME interactions is crucial for effective cancer immunotherapies. By analyzing factors affecting T cell mobility and function, researchers can develop strategies to enhance immune infiltration and sustain cytotoxic activity, leveraging insights from single-cell technologies and TME research to improve therapeutic outcomes [23, 6].

5.3 Granzyme B and Cytotoxic Lymphocytes in the TME

Granzyme B (GrB) and cytotoxic lymphocytes, including CTLs and NK cells, are pivotal in the tumor microenvironment (TME), impacting cancer progression and treatment outcomes. The TME's complex interplay of cellular and molecular components affects immune cell function. GrB is particularly notable for inducing apoptosis in tumor cells, contributing to immune-mediated cancer eradication [23].

In the TME, CTL and NK cell functionality is modulated by factors like hypoxia, which induces proteomic changes in CTLs, affecting immune functions and cytotoxic molecule expression, such as GrB. Quantitative analyses of protein changes under hypoxic conditions offer insights into environmental influences on immune cell function and anti-tumor responses [23].

GrB's role extends beyond tumor cell killing. The TME influences the local immune landscape, altering inflammatory conditions and interactions among immune cells, affecting tumor progression and treatment efficacy [23, 17, 11, 19]. Cytokines and chemokines secreted by TILs recruit more immune cells, enhancing responses, but the TME can also present barriers like inhibitory molecules and immunosuppressive cells, dampening immune responses and aiding tumor evasion.

Understanding GrB and cytotoxic lymphocyte interactions in the TME is crucial for advancing cancer immunotherapies, as these dynamics influence tumor progression, immune evasion, and therapeutic outcomes. Single-cell technologies have enabled detailed profiling of tumor-infiltrating immune cells, revealing their diversity and roles, informing targeted strategies [17, 6]. By elucidating

factors affecting GrB activity and immune function, strategies can be developed to enhance cytotoxic potential, improve infiltration, and overcome TME barriers, leading to better cancer treatment outcomes.

5.4 Challenges in Understanding TME Interactions

Studying tumor microenvironment (TME) interactions presents significant challenges, impacting cancer therapy development. A major challenge is tumor heterogeneity, mirrored by TME complexity, contributing to treatment resistance and complicating target identification. The TME's diverse cellular and molecular components, including fibroblasts, immune cells, and ECM, interact dynamically, influencing tumor progression and therapy responses. Understanding these relationships is essential for targeted treatments and improving efficacy [6, 17, 16, 11].

The TME's complexity also affects tumor progression and immune responses. The intricate network of interactions among cancer, immune, stromal cells, and ECM creates a multifaceted environment promoting tumor growth and immune evasion. Identifying therapeutic targets is challenging, as interventions must consider the TME's dynamic nature and adaptability to therapeutic pressures [11].

Moreover, the generalizability of TME study methods across populations and tumor types poses additional challenges. Predictive accuracy varies with datasets, highlighting the need for robust models accommodating variability in tumor contexts [20]. This variability emphasizes developing personalized strategies targeting each patient's unique TME characteristics.

TME interaction complexities necessitate a multifaceted approach to cancer research, as these interactions influence tumor development, immune evasion, and therapy effectiveness. Understanding TME heterogeneity requires innovative models and profiling techniques to enhance targeted therapy development and improve patient outcomes [6, 17]. Advanced modeling and high-throughput data analysis can unravel TME complexities, leading to more effective cancer therapies.

6 Therapeutic Implications and Future Directions

Category	Feature	Method
Enhancing Cytotoxic Lymphocyte Activity	Cytotoxic Enhancement Strategies	HRMS[23], SIA[8], KO-iPSCs[9]
Stochastic Modeling and Personalized Therapy	Stochastic Modeling	MSSN[13]
Future Research Directions	Cancer Therapy Strategies	GrB-Fc-4D5[2], GrB-SPIONs[3], KCACL[4]
	Tumor Environment Analysis	PMBT[20]
	Immune Modulation Approaches	TFR-TFH[7]

Table 1: This table provides a comprehensive summary of current and emerging methodologies in cancer therapy, focusing on enhancing cytotoxic lymphocyte activity, stochastic modeling, and future research directions. It categorizes the methods based on their application areas, including cytotoxic enhancement strategies, stochastic modeling, cancer therapy strategies, tumor environment analysis, and immune modulation approaches, with references to relevant studies.

Exploring therapeutic strategies in cancer treatment involves enhancing existing therapies' effectiveness through innovative approaches. Table 1 offers an organized overview of innovative therapeutic strategies and research directions in cancer treatment, highlighting key methodologies and their potential impact on enhancing treatment efficacy. Granzyme B (GrB), a serine protease involved in apoptosis and immune modulation, emerges as a promising target, especially in thyroid cancer. The following subsection delves into GrB as a therapeutic target, highlighting novel approaches and their implications.

6.1 Targeting Granzyme B in Thyroid Cancer Therapy

Granzyme B (GrB) targeting in thyroid cancer enhances treatment efficacy by leveraging its apoptotic and immune-modulatory functions. As a product of cytotoxic lymphocytes, GrB induces apoptosis in cancer cells, making it a viable therapeutic target [1]. Integrating GrB-targeted strategies with current therapies can significantly improve outcomes by utilizing the immune system's cancer cell elimination capabilities.

Innovative strategies include recombinant fusion proteins like GrB-Fc-4D5, which increase cytotoxicity against HER2-positive tumors [2]. This method underscores engineered proteins' potential

to selectively deliver GrB to cancer cells, amplifying apoptotic effects while minimizing off-target impacts. Similarly, functionalizing superparamagnetic iron oxide nanoparticles (SPIONs) with GrB targets mHsp70-positive tumors, enhancing therapeutic precision by exploiting tumor-specific mHsp70 expression [3].

The tumor microenvironment (TME) significantly influences GrB activity and therapeutic efficacy. Integrated strategies combining TME-targeted therapies with GrB-based interventions could improve outcomes by overcoming immunosuppressive barriers within the TME [11]. Factors such as age and cytomegalovirus (CMV) infection, affecting immune function and vaccine responses, necessitate tailoring GrB-targeted therapies for optimal efficacy [5]. In papillary thyroid carcinoma (PTC), elevated NK cell populations correlate with lymph node metastasis risk, indicating potential GrB therapeutic applications [4].

6.2 Enhancing Cytotoxic Lymphocyte Activity

Method Name	Mechanisms of Action	Intervention Strategies	Therapeutic Integration
SIA[8]	Granule Exocytosis Pathway	Il-2 Treatment	Synergistic Effects
PMBT[20]	Perforin And Granzymes	Cytokines, Inhibitors, Lymphocytes	Traditional Treatments, Immunomodulatory
KO-iPSCs[9]	Immune Recognition	Engineered Lymphocytes	Synergistic Effects
HRMS[23]	Cytolytic Molecules	Cytokine Production Analysis	Enhance T Cell

Table 2: Overview of various methods for enhancing cytotoxic lymphocyte activity, detailing their mechanisms of action, intervention strategies, and therapeutic integration. The table includes methods such as SIA, PMBT, KO-iPSCs, and HRMS, highlighting their specific roles in immune modulation and cancer treatment.

Enhancing cytotoxic lymphocytes like CTLs and NK cells is crucial for improving cancer treatment outcomes. These immune cells are vital in recognizing and destroying tumor cells through mechanisms involving perforin and granzymes, including GrB [8]. Strategies focus on overcoming TME immunosuppressive barriers and boosting lymphocyte cytotoxic potential. Table 2 provides a comprehensive analysis of different approaches to enhance cytotoxic lymphocyte activity, emphasizing their mechanisms, intervention strategies, and therapeutic applications.

Approaches include cytokines and immune checkpoint inhibitors to modulate the immune landscape and enhance CTL and NK cell functions. By blocking inhibitory signals and promoting co-stimulatory pathways, these interventions rejuvenate exhausted lymphocytes, improving infiltration and persistence within the TME [20]. Engineered lymphocytes, such as CAR T cells, offer another avenue, targeting specific tumor antigens and selectively destroying cancer cells [9].

Small molecule inhibitors and epigenetic modulators augment cytotoxic lymphocyte activity by altering gene expression involved in immune regulation and cytotoxicity, enhancing GrB and perforin production [23]. Developing combination therapies that integrate traditional treatments with immunomodulatory agents holds potential for enhanced cytotoxic lymphocyte activity, achieving synergistic effects that improve efficacy and reduce resistance [17].

6.3 Combination Therapies and Tumor Microenvironment

Combination therapies targeting the TME offer a promising approach to overcoming cancer progression challenges. The TME, with its diverse cellular and molecular components, modulates cancer cell behavior and therapeutic resistance. By targeting multiple TME components, combination therapies disrupt supportive interactions facilitating tumor growth and immune evasion, enhancing existing treatments' efficacy [17].

Developing combination therapies involves integrating conventional treatments with targeted agents and immunotherapies that modulate the TME. Combining immune checkpoint inhibitors with cytotoxic agents enhances immune response by inhibiting negative regulatory signals, facilitating CTL infiltration and activation within the TME. Advances in single-cell technologies reveal diverse phenotypes and functional roles of tumor-infiltrating immune cells, informing novel immunotherapeutic strategies tailored to individual profiles [17, 23, 6, 25].

Targeting metabolic reprogramming within the TME is another avenue for combination therapy development. Inhibiting key metabolic pathways supporting cancer cell survival can sensitize tumors

to immune-mediated killing and enhance immunotherapy effectiveness. This strategy addresses metabolic interdependencies limiting anti-tumor immune responses, potentially improving clinical outcomes [6, 18, 17].

Future research should focus on developing combination therapies targeting multiple TME components, optimizing dosing regimens, and understanding interactions between therapeutic modalities. By leveraging insights into TME complexity and heterogeneity, researchers can design more effective strategies to improve patient outcomes [17].

6.4 Stochastic Modeling and Personalized Therapy

Stochastic modeling is crucial for developing personalized cancer therapies, capturing tumor biology and treatment response variability and complexity. The stochastic nature of cancer progression and outcomes is influenced by genetic, epigenetic, and environmental factors [16]. Incorporating stochastic elements into models allows simulation of probabilistic cellular processes and prediction of individual patient outcomes.

Minimal signaling network models elucidate stochastic variability in apoptosis signaling and other critical pathways in cancer progression [13]. These models explore intrinsic fluctuations in protein expression and signaling interactions, contributing to heterogeneity in treatment responses. By capturing these dynamics, stochastic models provide insights into factors driving therapeutic outcome variability and identify intervention targets.

In personalized therapy, stochastic modeling tailors treatment strategies to unique tumor characteristics, integrating patient-specific data like genomic profiles to predict individual responses. This approach facilitates optimal regimen identification by leveraging insights into the TME's role in cancer progression and response. Understanding cancer cell and TME component interactions allows clinicians to design therapies enhancing efficacy while minimizing adverse effects [6, 17, 24, 11].

Stochastic modeling also informs combination therapy design by identifying synergistic interactions among modalities. By simulating drug combinations' effects on tumor dynamics, researchers prioritize strategies enhancing anti-tumor activity and overcoming resistance mechanisms, particularly relevant in the TME context [17].

Stochastic modeling is essential in precision medicine, providing a framework for developing personalized therapies. This approach accounts for tumor biology complexity and variability, including genetic, epigenetic, and stochastic factors contributing to cell variability in responses. Integrating systems biology and simulations enhances understanding of tumor heterogeneity and facilitates targeted intervention designs considering microenvironmental influences [27, 21, 16, 13, 17]. Leveraging these models will advance cancer treatment and improve outcomes through targeted interventions.

6.5 Future Research Directions

Method Name	Model Development	Therapeutic Strategies	Immune Mechanisms
GrB-Fc-4D5[2]	Advanced Models Incorporating	Grb-based Therapies	Immune Response Modulation
GrB-SPIONs[3]	Advanced Models	Grb-based Therapies	Immune Response Modulation
PMBT[20]	Prognostic Model Development	Personalized Treatment Strategies	Immune Response Modulation
KCACL[4]	Future Research	Immunotherapeutic Strategies	Lymphocyte Dysfunction
TFR-TFH[7]	-	Potential Therapeutic Insights	Regulatory Functions

Table 3: Summary of various research methods focusing on model development, therapeutic strategies, and immune mechanisms in the context of thyroid cancer. The table highlights the integration of GrB-based therapies, personalized treatment strategies, and immune response modulation, providing insights into future research directions.

Table 3 presents a comprehensive overview of current research methods aimed at advancing model development, therapeutic strategies, and understanding immune mechanisms in thyroid cancer. Future research should prioritize developing sophisticated models incorporating additional states and interactions, focusing on antigen presence and types on immune responses. This approach will enhance understanding of the immune microenvironment's role in thyroid cancer progression [10]. Integrating single-cell analysis with computational modeling will provide insights into cell variability, allowing for personalized treatment strategies [16].

Exploring GrB-based therapies, such as GrB-Fc-4D5, in combination with other modalities should be a focal point, with clinical trials assessing efficacy in HER2-positive tumors [2]. Optimizing GrB-functionalized nanoparticles, like SPIONs, for clinical applications and investigating their potential in combination therapies could significantly advance targeted treatments [3].

Understanding GrB expression's mechanistic basis and impact on immune responses is crucial for developing strategies to enhance immune-mediated cancer cell eradication [5]. Further research should investigate specific mechanisms by which GrB contributes to inflammation and fibrosis, improving thyroid cancer treatment [1].

The TME's role in modulating immune responses and outcomes necessitates exploration. Validating models like PMBT in diverse cohorts and refining them to include relevant factors will be essential for application across cancer types [20]. Research should focus on elucidating molecular interactions within the TME and targeting them to improve responses [24].

Investigating lymphocyte dysfunction mechanisms in papillary thyroid carcinoma (PTC) and identifying therapeutic targets within the immune microenvironment will be vital for enhancing efficacy [4]. Exploring T follicular regulatory (TFR) cell suppression of cytotoxic T follicular helper (TFH) cells could provide insights into enhancing immune responses [7].

Optimizing therapies to enhance T cell retention within the TME while managing non-specific influx will be crucial for improving immunotherapy efficacy by ensuring sustained immune cell activity [19]. Further investigation into NK cell-based immunotherapies' timing and conditions, as well as understanding NK cell dysfunction mechanisms in acute myeloid leukemia (AML), will be essential for optimizing strategies [22].

Feature	Targeting Granzyme B in Thyroid Cancer Therapy	Enhancing Cytotoxic Lymphocyte Activity	Combination Therapies and Tumor Microenvironment
Therapeutic Strategy	Grb-targeted Therapies	Boost Lymphocyte Function	Integrative Approach
Target Mechanism	Induces Apoptosis	Immune Modulation	Tme Modulation
Potential Impact	Improved Treatment Efficacy	Enhanced Tumor Destruction	Overcome Resistance

Table 4: This table provides a comparative analysis of various therapeutic strategies targeting Granzyme B in thyroid cancer therapy, enhancing cytotoxic lymphocyte activity, and employing combination therapies within the tumor microenvironment. It highlights the therapeutic strategies, target mechanisms, and potential impacts of these approaches, offering insights into their roles in improving treatment efficacy and overcoming resistance in cancer therapy.

7 Conclusion

This survey emphasizes the critical function of Granzyme B (GrB) in the immune response against thyroid cancer, positioning it as a promising therapeutic target. As a serine protease released by cytotoxic lymphocytes, GrB is essential for inducing apoptosis in cancer cells, thereby controlling tumor progression. The complex interplay between GrB and the tumor microenvironment (TME) significantly affects immune cell infiltration and function, which in turn influences treatment outcomes. A thorough understanding of tumor-infiltrating immune cell (TIIC) heterogeneity and dynamics is vital for enhancing the efficacy of immunotherapies [6].

The findings support personalized therapeutic strategies that take into account the distinct characteristics of individual TME, thereby optimizing treatment effectiveness. Ongoing research is crucial to fully harness the immune system's capabilities in cancer treatment, particularly focusing on the interactions among GrB, cytotoxic lymphocytes, and the TME. By deepening our understanding of these intricate relationships, we can develop targeted interventions that leverage the immune system's potential, paving the way for improved cancer treatment strategies and patient outcomes.

References

[1] Francesca Velotti, Ilaria Barchetta, Flavia Agata Cimini, and Maria Gisella Cavallo. Granzyme b in inflammatory diseases: apoptosis, inflammation, extracellular matrix remodeling, epithelial-to-mesenchymal transition and fibrosis. *Frontiers in immunology*, 11:587581, 2020.

[2] Lawrence H Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A Mohamedali, Yu J Cao, Walter N Hittelman, and Michael G Rosenblum. Development of a human immuno-oncology therapeutic agent targeting her2: targeted delivery of granzyme b. *Journal of Experimental & Clinical Cancer Research*, 38:1–14, 2019.

[3] Maxim Shevtsov, Stefan Stangl, Boris Nikolaev, Ludmila Yakovleva, Yaroslav Marchenko, Ruslana Tagaeva, Wolfgang Sievert, Emil Pitkin, Anton Mazur, Peter Tolstoy, et al. Granzyme b functionalized nanoparticles targeting membrane hsp70-positive tumors for multimodal cancer theranostics. *Small*, 15(13):1900205, 2019.

[4] Xiaogang Liu, Honggang Liu, Lu Wang, Yubing Han, Linghong Kong, and Xinpeng Zhang. Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the braf v600e mutation. *Diagnostic Pathology*, 19(1):29, 2024.

[5] Chris P Verschoor, Emilie Picard, Melissa K Andrew, Laura Haynes, Mark Loeb, Graham Pawelec, and George A Kuchel. Nk-and t-cell granzyme b and k expression correlates with age, cmv infection and influenza vaccine-induced antibody titres in older adults. *Frontiers in Aging*, 3:1098200, 2023.

[6] Yuanyuan Zhang and Zemin Zhang. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cellular & molecular immunology*, 17(8):807–821, 2020.

[7] Markus M Xie, Shuyi Fang, Qiang Chen, Hong Liu, Jun Wan, and Alexander L Dent. Follicular regulatory t cells inhibit the development of granzyme b–expressing follicular helper t cells. *JCI insight*, 4(16):e128076, 2019.

[8] Jamie A Lopez, Tahereh Noori, Adrian Minson, Lu Li Jovanoska, Kevin Thia, Michael S Hildebrand, Hedieh Akhlaghi, Phillip K Darcy, Michael H Kershaw, Natasha J Brown, et al. Bi-allelic mutations in stxbp2 reveal a complementary role for stxbp1 in cytotoxic lymphocyte killing. *Frontiers in immunology*, 9:529, 2018.

[9] Mackenzie Parmenter, Christopher B Rohde, and Matthew Angel. Cytotoxic lymphocytes derived from b2m-knockout ipscs show enhanced expansion and cytokine controlled cytotoxicity in vitro. In *MOLECULAR THERAPY*, volume 30, pages 346–346. CELL PRESS 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA, 2022.

[10] Maria A. Avino-Diaz. A probabilistic regulatory network for the human immune system, 2007.

[11] Yi Xiao and Dihua Yu. Tumor microenvironment as a therapeutic target in cancer. *Pharmacology & therapeutics*, 221:107753, 2021.

[12] Andrei Zinovyev, Simon Fourquet, Laurent Tournier, Laurence Calzone, and Emmanuel Barillot. Cell death and life in cancer: mathematical modeling of cell fate decisions, 2013.

[13] Subhadip Raychaudhuri. A minimal model of signaling network elucidates cell-to-cell stochastic variability in apoptosis, 2010.

[14] Oussema Souiai, Fatma Guerfali, Slimane Ben Miled, Christine Brun, and Alia Benkahla. In silico prediction of protein-protein interactions in human macrophages, 2015.

[15] Peter J Burke. Mitochondria, bioenergetics and apoptosis in cancer. *Trends in cancer*, 3(12):857–870, 2017.

[16] Joanna Skommer, Subhadip Raychaudhuri, and Donald Wlodkowic. Timing is everything: on the stochastic origins of cell-to-cell variability in cancer cell death decisions, 2011.

[17] Catarina Roma-Rodrigues, Rita Mendes, Pedro V Baptista, and Alexandra R Fernandes. Targeting tumor microenvironment for cancer therapy. *International journal of molecular sciences*, 20(4):840, 2019.

[18] Kathrin Renner, Katrin Singer, Gudrun E Koehl, Edward K Geissler, Katrin Peter, Peter J Siska, and Marina Kreutz. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. *Frontiers in immunology*, 8:248, 2017.

[19] Tiffany C Blair, Alejandro F Alice, Lauren Zebertavage, Marka R Crittenden, and Michael J Gough. The dynamic entropy of tumor immune infiltrates: the impact of recirculation, antigen-specific interactions, and retention on t cells in tumors. *Frontiers in Oncology*, 11:653625, 2021.

[20] Zihang Zeng, Jiali Li, Nannan Zhang, Xueping Jiang, Yanping Gao, Liexi Xu, Xingyu Liu, Jiarui Chen, Yuke Gao, Linzhi Han, Jiangbo Ren, Yan Gong, and Conghua Xie. Tumor microenvironment-based gene signatures divides novel immune and stromal subgroup classification of lung adenocarcinoma, 2019.

[21] Arnulfo Castellanos-Moreno, Alejandro Castellanos-Jaramillo, Adalberto Corella-Madueño, Sergio Gutiérrez-López, and Rodrigo Rosas-Burgos. Stochastic model for computer simulation of the number of cancer cells and lymphocytes in homogeneous sections of cancer tumors, 2014.

[22] Jérôme Rey, Cyril Fauriat, Eloïse Kochbati, Florence Orlanducci, Aude Charbonnier, Evelyne D'incan, Pascale Andre, François Romagne, Bernadette Barbarat, Norbert Vey, et al. Kinetics of cytotoxic lymphocytes reconstitution after induction chemotherapy in elderly aml patients reveals progressive recovery of normal phenotypic and functional features in nk cells. *Frontiers in immunology*, 8:64, 2017.

[23] Sarah H Ross, Christina M Rollings, and Doreen A Cantrell. Quantitative analyses reveal how hypoxia reconfigures the proteome of primary cytotoxic t lymphocytes. *Frontiers in immunology*, 12:712402, 2021.

[24] J-J Wang, K-F Lei, and FJERMPS Han. Tumor microenvironment: recent advances in various cancer treatments. *European Review for Medical & Pharmacological Sciences*, 22(12), 2018.

[25] Pierre Golstein and Gillian M Griffiths. An early history of t cell-mediated cytotoxicity. *Nature Reviews Immunology*, 18(8):527–535, 2018.

[26] E Obeng. Apoptosis (programmed cell death) and its signals-a review. *Brazilian Journal of Biology*, 81(4):1133–1143, 2020.

[27] Anna Ochab-Marcinek and Ewa Gudowska-Nowak. Population growth and control in stochastic models of cancer development, 2004.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.